INDBInternet News Database 2.5 Updated 1 min ago · 306 sources Show or hide images Light or dark

GSK won U.S. approval for its second lung cancer drug from the Nuvalent deal

Save Like Comments Compare coverage
Image from Quartz

Summary

The FDA granted accelerated approval to neladalkib, sold as Nelkarmi, for ALK-positive non-small cell lung cancer

Description from Quartz.

Who is covering this

  1. Medpagetoday Center Factuality: Mostly factual US
    FDA Adds Another Player in ALK-Positive Lung Cancer

    (MedPage Today) -- The FDA granted accelerated approval to the third-generation ALK inhibitor neladalkib (Nelkarmi) for previously treated advanced ALK-positive non-small cell lung cancer (NSCLC), making it the seventh approved agent in a crowded...

  2. Quartz Leans left Factuality: High US
    GSK won U.S. approval for its second lung cancer drug from the Nuvalent deal

    The FDA granted accelerated approval to neladalkib, sold as Nelkarmi, for ALK-positive non-small cell lung cancer

Comments

Comments need JavaScript.